Gene-Guided drug cocktail shows promise for tough gynaecological cancers

NCT ID NCT04065269

First seen Feb 21, 2026 · Last updated May 13, 2026 · Updated 8 times

Summary

This study tests a new drug (ceralasertib) alone or with either a targeted therapy (olaparib) or an immunotherapy (durvalumab) in 174 people with advanced gynaecological cancers that have returned after treatment. The goal is to see if these combinations work better in cancers with or without a specific gene change (ARID1A). Participants must have certain cancer types like clear cell or endometrioid ovarian or endometrial cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GYNAECOLOGICAL CANCERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Imperial College NHS Trust

    London, United Kingdom

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 2M9, Canada

  • Royal United Hospital

    Bath, BA1 3NG, United Kingdom

  • The Beatson

    Glasgow, United Kingdom

  • The Christie

    Manchester, United Kingdom

  • The Ottawa Hospital Cancer Centre

    Ottawa, Ontario, K1H 8L6, Canada

  • The Royal Marsden NHS Foundation Trust

    London, SW3 6JJ, United Kingdom

  • University of Montreal Hospital Centre

    Montreal, Quebec, H2X 3E4, Canada

  • Western General Hospital

    Edinburgh, United Kingdom

Conditions

Explore the condition pages connected to this study.